Materials • Major Chemicals
$13.80 ▲ +0.19
(+1.40%)
MKT CAP: $124.3M • VOL: 23.4K
52W L $12 52W H $18
ACNT // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $74.9M | $80.8M | $193.2M |
| YoY Revenue Growth % | -7.2% | -58.2% | — |
| Gross Profit | $17.2M | $10.7M | — |
| Gross Margin % | 23.0% | 13.2% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$7.0M | -$10.8M | -$37.4M |
| Operating Margin % | -9.4% | -13.4% | -19.4% |
| Net Income (GAAP) | $867.0K | -$13.6M | -$26.6M |
| EBITDA (Normalized) | -$5.8M | -$9.9M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$519.0K | $14.7M | $23.1M |
| Capital Expenditures (CapEx) | $1.5M | $1.1M | — |
| Free Cash Flow (FCF) | -$2.1M | $13.6M | $23.1M |
| FCF Margin % | -2.8% | 16.8% | 11.9% |
| Return on Invested Capital (ROIC %) | -18.9% | -11.0% | — |
| Cash & Short-Term Equivalents | $57.6M | $16.1M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $87.0M | $93.5M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ACNT.